Search Results - daniel+geschwind

3 Results Sort By:
NPEPPS Enhancers for Treating Tau-Induced Neurodegeneration (UCLA Case No. 2018-161)
UCLA researchers from the Department of Neurology have developed first-in-class small-molecule activators of NPEPPS that effectively lower pathological tau, offering a novel disease-modifying strategy for Alzheimer’s and other neurodegenerative disorders. BACKGROUND: Neurodegenerative dementias such as Alzheimer’s Disease (AD) and progressive...
Published: 10/22/2025   |   Inventor(s): Daniel Geschwind, Robert Damoiseaux, Liting Deng, Michael Jung, Jennifer Murphy, Gaoyuan Ma
Keywords(s):  
Category(s): Therapeutics > CNS and Neurology, Diagnostic Markers > Targets And Assays
2015-016 Frataxin Knock-Down Mouse Model for Friedreich's Ataxia
A Novel Mouse Model for Friedreich's AtaxiaBACKGROUNDFriedreich’s Ataxia (FRDA) is a debilitating, life‐shortening, degenerative neuromuscular disorder that is caused by severely reduced levels of frataxin. It affects about one in 50,000 people in the United States, but currently there are no treatments. Therefore the generation of corresponding...
Published: 7/9/2025   |   Inventor(s): Daniel Geschwind, Vijayendran Chandran
Keywords(s): Animal Models, Cns
Category(s): Life Science Research Tools > Animal Models, Therapeutics > CNS and Neurology
2008-456 BIOMARKERS IN FRIEDREICH'S ATAXIA
Biomarkers in Friedreich's AtaxiaSUMMARYUCLA researchers in the Department of Neurology have identified multiple biomarkers for Friedreich's Ataxia.BACKGROUNDFriedreich's Ataxia (FRDA) is a progressive neurodegenerative disease that affects the peripheral nerves and the cerebellum. Mutations resulting in loss of function of the iron-binding protein,...
Published: 3/6/2025   |   Inventor(s): Daniel Geschwind, Giovanni Coppola
Keywords(s): Cns, Diagnostic Markers & Platforms
Category(s): Diagnostic Markers, Therapeutics > CNS and Neurology